Jade Biosciences, Inc. 8-K

What Happened

• Jade Biosciences, Inc. announced on June 3, 2026 (filed in an 8-K) that it entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and UBS Securities LLC to sell 10,000,000 shares of its common stock at $15.00 per share. The underwriters will purchase the shares from the company at $14.10 per share. The offering is expected to close on June 5, 2026, subject to customary closing conditions.

Key Details

• Offering size: 10,000,000 shares at $15.00 per share (gross proceeds $150.0M).
• Underwriters’ purchase price: $14.10 per share; 30‑day option to purchase up to 1,500,000 additional shares at the public offering price.
• Expected net proceeds: approximately $140.3 million (or about $161.5 million if the underwriters’ option is exercised in full), after underwriting discounts, commissions and estimated expenses.
• Offering made pursuant to the company’s effective Form S-3 shelf registration; prospectus supplement and prospectus were filed June 3, 2026.

Why It Matters

• This offering will raise significant cash for Jade Biosciences (roughly $140M–$161.5M net), which can strengthen the company’s balance sheet and support its operations or strategic plans. The filing does not specify intended uses of proceeds.
• Issuing these shares (and any exercised option shares) will increase the number of outstanding shares and dilute existing shareholders’ ownership. Investors should watch the closing of the offering and any company disclosures about use of proceeds and future capital plans.
• The transaction is subject to customary closing conditions and contains forward-looking statements; actual outcomes depend on market conditions and satisfaction of those conditions.